Skip to main content
. Author manuscript; available in PMC: 2023 Oct 23.
Published in final edited form as: Cell Rep. 2023 Jan 25;42(2):112040. doi: 10.1016/j.celrep.2023.112040

Fig. 6. Agonistic JAML antibody treatment impedes tumor growth.

Fig. 6.

A,B, Tumor volume of C57BL/6J (a, n=10 mice for isotype control group and n=9 for anti-PD-1 and anti-JAML groups, P=0.0141 for isotype control vs anti-JAML and P=0.0227 for anti-PD-1 vs anti-JAML) or CD8−/− (B, n=7 mice/group for isotype control and anti-JAML and n=6 mice/group for anti-PD-1) mice s.c. inoculated with B16F10-OVA cells and treated with isotype control antibodies, anti-PD-1 antibodies or anti-JAML antibodies at indicated time points. C,D, Tumor volume (c, P<0.0001 for B16F10 vs OT-Iwt, P=0.0014 for B16F10 vs OT-I JAML−/−, P=0.033 for OT-Iwt vs OT-I JAML−/−) (n=13 mice/group for the control group, n=8 mice/group for OT-Iwt and n=10 mice/group for OT-I JAML−/−), and frequencies of tumor-infiltrating OT-I T cells (D, n=6 mice/group for OT-Iwt and n=8 mice/group for OT-I JAML−/−) of mice s.c. inoculated with B16F10-OVA cells and treated with 1×106 adoptively transferred wildtype OT-I T cells or JAML−/− OT-I T cells at day 6 after tumor inoculation. E, Tumor volume of mice s.c. inoculated with CXADR+/+ or CXADR−/− MC38-OVA cells and treated with either isotype control antibodies or anti-JAML antibodies at indicated time points (n=8 mice/group for CXADR+/+ + isotype control and n=7 mice/group for CXADR+/+ + anti-JAML, P=0.61; n=8 mice/group for CXADR−/− + isotype control and n=7 mice/group for CXADR−/− + anti-JAML, P=0.041). All data are mean +/− S.E.M and are representative of at least 2 independent experiments. Significance for comparisons was computed using two-tailed Mann-Whitney test; *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.